Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs

In short, for those who have faced barriers to injectable therapy, whether practical, psychological or social, a daily pill may open a door that was previously closed
Introduction Obesity, defined as a body mass index (BMI) 30, affects around 42% of adults in the United States ( 2 ) than men (11.5% vs
Remember how a perk of melanotan was that it didnt rely on UV rays to deepen your skin tone
Closing: The Clinical Bottom Line on What Is MOTS-c MOTS-c is a mitochondrial-derived signaling peptide with a narrow, high-confidence clinical use case: amplifying AMPK-driven metabolic function in patients who have plateaued with diet, training, and standard interventions
This helps to regulate blood sugar and digestion rate, which controls appetite & food cravings